Mario Negri Institute For Pharmacological Research

This study looks at whether adding olaparib to standard bevacizumab treatment can help keep advanced ovarian cancer from coming back. About 190 women with a specific genetic marker (HRD-positive) will receive this combination as maintenance therapy after initial chemotherapy. The…

This study looks at two different ways to give anti-rejection drugs to kidney transplant patients. One group gets a single dose of a drug called RATG, while the other gets seven doses over a week. The goal is to see which approach causes fewer side effects like low blood cell cou…

This study looks at how well two different blood tests (creatinine and cystatin C) measure kidney function in people with nephrotic syndrome. Researchers will use stored blood samples from 50 people who took part in earlier trials. The goal is to see which test gives a more accur…

This study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: aHUS and C3G. Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers. The goal is to find markers that help doctors choose the right treatment …

This study gathers medical images (MRI, CT, ultrasound) and related health data from 300 adults—both healthy volunteers and those with kidney or brain diseases. The goal is to create a secure collection that scientists can use for future not-for-profit research. No new treatments…

This study looks back at medical records from 70 adults with advanced polycystic kidney disease (ADPKD) who are taking the drug octreotide LAR. The goal is to see if baseline factors like total kidney volume can predict how quickly their kidney function declines over time. No new…

This study looks at using artificial intelligence to create fake but realistic health data based on real patient records for a rare kidney disease called ADPKD. Researchers will test whether this simulated data can be used to run virtual clinical trials, which could make future r…